AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
ABVC Biopharma Inc (NASDAQ:ABVC)
1.25 USD
+0.040 3.306%Sponsored Reports
Loading...
| Previous Close (in USD) | 1.21 |
|---|---|
| Change | +0.040 3.306% |
| 52 W H/L (in USD) | 5.480/0.850 |
| EBITDA (in USD) | -7.126M |
| PE Ratio | -- |
| Volume | 88892 |
| Diluted Eps TTM | -0.39 |
| Total Assets (in USD) | 21.062M |
|---|---|
| Total Liabilities (in USD) | 7.765M |
| Revenue TTM (in USD) | 0.798M |
| Cash (in USD) | 0.681M |
| Market Cap (in USD) | 33.328 M |
| Revenue Per Share TTM | 0.046 |
| Gross Profit TTM (in USD) | 0.798M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
ABVC Biopharma Inc
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
44370 Old Warm Springs Boulevard, Fremont, CA, United States, 94538
510 668 0881
Employees: 16
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Eugene Jiang | Chairman & Chief Bus. Officer | 1986 |
| 2. | Dr. Howard Doong M.D., Ph.D. | Pres & CEO | 1957 |
| 3. | Dr. Chi-Hsin King Ph.D. | Chief Scientific Officer | 1948 |
| 4. | Dr. Tsung-Shann Jiang Ph.D. | Chief Strategy Officer, Member of Scientific Advisory Board & Director | 1954 |
| 5. | Mr. Leeds Chow | Chief Financial Officer | NA |
| 6. | Mr. Eugene Jiang | Chairman & Chief Business Officer | 1986 |
| 7. | Dr. Uttam Yashwant Patil Ph.D. | Chief Executive Officer | 1986 |
| 8. | Mr. Leeds Chow | CFO & Principal Accounting Officer | 1989 |
| 9. | Dr. Tsung-Shann Jiang EMBA, Ph.D. | Chief Scientific Officer, Chief Strategy Officer & Director | 1954 |
| 10. | Dr. Uttam Yashwant Patil Ph.D. | CEO & Interim CFO | 1986 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-1.160 2.253% | 51.06 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.820 1.602% | 51.2 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-0.380 0.078% | 483.51 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-2.250 0.331% | 676.05 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -8.353M | -5.37M | -8.025M | -15.515M | -11.211M |
| Minority Interest | 0.468M | 0.356M | 0.395M | -0.111M | -0.803M |
| Net Income | -7.909M | -4.903M | -7.788M | -16.312M | -12.036M |
| Selling General Administrative | 7.03M | 5.035M | 5.554M | 13.104M | 11.053M |
| Gross Profit | 0.796M | 0.509M | -0.15M | 0.683M | 0.351M |
| Reconciled Depreciation | 0.505M | 0.201M | 0.029M | 0.024M | 0.012M |
| Ebit | -7.151M | -4.544M | -6.711M | -15.114M | -11.345M |
| Ebitda | -6.646M | -4.343M | -6.331M | -14.82M | -11.128M |
| Depreciation And Amortization | 0.505M | 0.201M | 0.38M | 0.295M | 0.217M |
| Operating Income | -7.151M | -4.705M | -6.767M | -15.114M | -11.345M |
| Other Operating Expenses | 7.151M | 5.215M | 6.919M | 16.084M | 11.701M |
| Interest Expense | 0.416M | 0.826M | 1.314M | 0.294M | 0.227M |
| Tax Provision | 0.024M | -0.111M | 0.256M | 0.798M | 0.825M |
| Interest Income | 0.167M | 0.087M | 0.185M | 0.188M | 0.043M |
| Net Interest Income | -0.249M | -0.739M | -2.308M | -0.106M | -0.184M |
| Income Tax Expense | 0.024M | -0.111M | 0.256M | 0.798M | 0.825M |
| Total Revenue | 0.796M | 0.51M | 0.152M | 0.97M | 0.356M |
| Total Operating Expenses | 6.646M | 5.214M | 6.617M | 15.798M | 11.696M |
| Cost Of Revenue | 0.505M | 0.001M | 0.302M | 0.286M | 0.005M |
| Total Other Income Expense Net | -1.202M | -0.664M | -1.258M | -0.4M | 0.134M |
| Net Income From Continuing Ops | -8.377M | -5.259M | -10.91M | -16.312M | -12.036M |
| Net Income Applicable To Common Shares | - | - | - | -16.423M | -12.839M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 21.062M | 7.54M | 14.944M | 9.855M | 13.698M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 1.756M | 0.096M | 0.101M | 0.15M | 1.95M |
| Total Liab | 7.765M | 6.816M | 6.362M | 6.24M | 4.828M |
| Total Stockholder Equity | 11.112M | 1.226M | 8.84M | 3.099M | 8.844M |
| Other Current Liab | 4.268M | 3.509M | 3.696M | 3.545M | 1.694M |
| Common Stock | 0.025M | 0.014M | 0.008M | 0.033M | 0.029M |
| Capital Stock | 0.025M | 0.014M | 0.008M | 0.033M | 0.029M |
| Retained Earnings | -76.858M | -68.95M | -65.42M | -54.904M | -38.481M |
| Good Will | - | - | - | - | 0M |
| Other Assets | - | - | - | - | 1.142M |
| Cash | 0.681M | 0.864M | 0.717M | 0.085M | 5.829M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 6.164M | 6.557M | 5.932M | 5.82M | 3.692M |
| Current Deferred Revenue | - | 0.081M | 0.08M | 0.011M | 0.011M |
| Net Debt | 2.791M | 2.34M | 1.734M | 2.97M | -2.717M |
| Short Term Debt | 1.872M | 2.967M | 2.044M | 2.263M | 1.987M |
| Short Long Term Debt | 1.555M | 1.79M | 1.469M | 1.894M | 1.827M |
| Short Long Term Debt Total | 3.473M | 3.204M | 2.451M | 3.055M | 3.112M |
| Other Stockholder Equity | 87.458M | 69.685M | 73.735M | 57.453M | 46.756M |
| Property Plant Equipment | - | - | - | - | 1.998M |
| Total Current Assets | 2.501M | 2.18M | 1.657M | 2.987M | 9.625M |
| Long Term Investments | 1.878M | 2.259M | 2.528M | 0.842M | 0.933M |
| Short Term Investments | 0.064M | 0.065M | 0.079M | 0.076M | 0.108M |
| Net Receivables | - | 1.155M | 0.76M | 1.369M | 1.713M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | 1.306M | 0.026M |
| Accounts Payable | - | - | 0.113M | - | 0M |
| Accumulated Other Comprehensive Income | 0.488M | 0.477M | 0.516M | 0.517M | 0.54M |
| Non Currrent Assets Other | 1.934M | 1.95M | 1.416M | 1.335M | 0.16M |
| Non Current Assets Total | 18.561M | 5.36M | 13.287M | 6.868M | 4.073M |
| Capital Lease Obligations | 1.918M | 0.64M | 0.809M | 1.161M | 1.472M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | - | 0M | -0.36M | -1.722M | -0.806M |
| Total Cashflows From Investing Activities | -1.209M | - | -0.36M | -1.722M | -0.806M |
| Total Cash From Financing Activities | 4.638M | 1.981M | 3.87M | 4.014M | 9.996M |
| Net Income | -7.909M | -5.259M | -7.788M | -16.312M | -12.036M |
| Change In Cash | 0.463M | 0.147M | -0.675M | -5.173M | 1.564M |
| Begin Period Cash Flow | 0.864M | 0.717M | 1.392M | 6.565M | 5.001M |
| End Period Cash Flow | 1.327M | 0.864M | 0.717M | 1.392M | 6.565M |
| Total Cash From Operating Activities | -2.986M | -1.809M | -4.187M | -7.398M | -7.598M |
| Depreciation | 0.505M | 0.201M | 0.38M | 0.024M | 0.012M |
| Other Cashflows From Investing Activities | -1.209M | - | -0.339M | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -0.011M | 0M | 0.069M | 0.026M | -0.026M |
| Sale Purchase Of Stock | 0M | -0.007M | 0M | - | - |
| Other Cashflows From Financing Activities | 4.638M | 1.941M | 2.594M | 0.35M | -0.61M |
| Capital Expenditures | 0.006M | 0M | 0.021M | 0.12M | 0.018M |
| Change In Working Capital | -0.615M | -0.408M | 0.309M | 0.636M | -1.614M |
| Other Non Cash Items | -2.371M | 0.884M | 2.726M | 0.353M | -0.091M |
| Free Cash Flow | -2.992M | -1.809M | -4.208M | -7.518M | -7.615M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Institutional Extnd Mkt Idx Tr | 3 months ago | 190574 |
| 2. | Fidelity Extended Market Index | 4 months ago | 105944 |
| 3. | Blackrock Extended Mkt Fund CF | 4 months ago | 55384 |
| 4. | Extended Equity Market Fund B | 6 months ago | 55384 |
| 5. | Extended Equity Market Fund E | 6 months ago | 55384 |
| 6. | Extended Equity Market Fund K | 3 months ago | 47158 |
| 7. | Fidelity Total Market Index | 4 months ago | 31053 |
| 8. | NT Ext Equity Mkt Idx Fd - L | 3 months ago | 27434 |
| 9. | Fidelity Series Total Market Index | 4 months ago | 27132 |
| 10. | Spartan Extended Market Index Pool F | 4 months ago | 19854 |
| 11. | Northern Trust Extended Eq Market Idx | 9 months ago | 19135 |
| 12. | Spartan Total Market Index Pool G | 4 months ago | 15648 |
| 13. | NT Ext Eq Mkt Indx Fd DC Lending Tier 5 | 3 months ago | 10825 |
| 14. | Fidelity Nasdaq Composite Index | 4 months ago | 6128 |
| 15. | Extended Equity Market Fund M | 3 months ago | 5542 |
| 16. | Dimensional US Core Equity 1 ETF | 3 months ago | 5207 |
| 17. | Dimensional US Sustainability Core 1 ETF | 3 months ago | 4354 |
| 18. | NT Ext Equity Mkt Idx Fd - NL | 3 months ago | 3925 |
| 19. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 3 months ago | 3075 |
| 20. | DFA US Core Equity 1 I | 4 months ago | 2666 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Group Inc | 6 months ago | 287937 |
| 2. | Geode Capital Management, LLC | 6 months ago | 202365 |
| 3. | State Street Corp | 9 months ago | 72800 |
| 4. | BlackRock Inc | 9 months ago | 56442 |
| 5. | Citadel Advisors Llc | 6 months ago | 55543 |
| 6. | Renaissance Technologies Corp | 6 months ago | 114263 |
| 7. | Northern Trust Corp | 9 months ago | 24821 |
| 8. | XTX Topco Ltd | 6 months ago | 11261 |
| 9. | Jane Street Group LLC | 6 months ago | 10867 |
| 10. | Tower Research Capital LLC | 6 months ago | 3193 |
| 11. | UBS Group AG | 9 months ago | 1849 |
| 12. | SIMPLEX TRADING, LLC | 6 months ago | 196 |
| 13. | Bank of America Corp | 9 months ago | 175 |
| 14. | Millennium Management LLC | 6 months ago | 0 |
| 15. | SBI Securities Co Ltd | 9 months ago | 0 |
| 16. | Northwestern Mutual Wealth Management Co | 6 months ago | 0 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...